Abigail G. Ayers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Abigail G. Ayers has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Samuel K. Sia
Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA
3 shared publications Christia M. Victoriano
Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA
2 shared publicationsAbdoulaye Sanogo
Department of Biomedical Engineering, Columbia University, New York, USA
1 shared publication- Aditya Sekhar
Department of Biomedical Engineering, Columbia University, New York, USA
1 shared publication Angela M. Tolwani
Department of Biomedical Engineering, Columbia University, New York, USA
1 shared publicationBianca Arraiza Carlo
Department of Biomedical Engineering, Harvard University, Cambridge, MA 02138, USA
1 shared publication
Latest Publications
- Open Access
- 20 April 2026
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 26 (10) , 3139-3152
Centrifuge-free separation of plasma from milliliters of whole blood for point-of-care diagnostics
PlasmaLIFT enables automated plasma separation from milliliters of whole blood by integrating immunomagnetic red blood cell depletion with dual-membrane filtration.
- 20 April 2026
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 26 (10) , 3139-3152
Open AccessCentrifuge-free separation of plasma from milliliters of whole blood for point-of-care diagnostics
PlasmaLIFT enables automated plasma separation from milliliters of whole blood by integrating immunomagnetic red blood cell depletion with dual-membrane filtration.
- Open Access
- 18 October 2024
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 24 (22) , 5124-5136
Integrated device for plasma separation and nucleic acid extraction from whole blood toward point-of-care detection of bloodborne pathogens
Sample preparation presents a major challenge in point-of-care (POC) diagnostic assays, including ones requiring whole blood as the starting specimen. This study presents an integrated sample preparation device – which we call PRECISE – that performs both plasma separation and nucleic acid extraction, enabling streamlined sample preparation from whole blood requiring only a commercially available blood collection tool and a syringe, and no other external equipment or electricity. Plasma separation is performed using a dual-membrane filter (which filters out blood components while limiting membrane clogging) integrated into the cartridge, and nucleic acid extraction is performed by users moving magnets (to mix the samples, and along a guided track). The plasma filtration demonstrated recovery on par with lab-based centrifugation, and the extraction module showed performance similar to benchtop-based magnetic bead extraction. A sample-to-result demonstration on 50 μL of whole blood spiked with virions of hepatitis C virus (HCV), operating the PRECISE cartridge in 16 minutes followed by benchtop PCR, showed a limit of detection (∼6770 IU mL−1) on the order of the minimal requirements of target product profile for POC HCV detection. Future work on the PRECISE cartridge, building on POC accessibility and fast sample preparation demonstrated in this work, may enable detection of bloodborne pathogens from whole-blood specimens collected at the POC.
- 18 October 2024
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 24 (22) , 5124-5136
Open AccessIntegrated device for plasma separation and nucleic acid extraction from whole blood toward point-of-care detection of bloodborne pathogens
Sample preparation presents a major challenge in point-of-care (POC) diagnostic assays, including ones requiring whole blood as the starting specimen. This study presents an integrated sample preparation device – which we call PRECISE – that performs both plasma separation and nucleic acid extraction, enabling streamlined sample preparation from whole blood requiring only a commercially available blood collection tool and a syringe, and no other external equipment or electricity. Plasma separation is performed using a dual-membrane filter (which filters out blood components while limiting membrane clogging) integrated into the cartridge, and nucleic acid extraction is performed by users moving magnets (to mix the samples, and along a guided track). The plasma filtration demonstrated recovery on par with lab-based centrifugation, and the extraction module showed performance similar to benchtop-based magnetic bead extraction. A sample-to-result demonstration on 50 μL of whole blood spiked with virions of hepatitis C virus (HCV), operating the PRECISE cartridge in 16 minutes followed by benchtop PCR, showed a limit of detection (∼6770 IU mL−1) on the order of the minimal requirements of target product profile for POC HCV detection. Future work on the PRECISE cartridge, building on POC accessibility and fast sample preparation demonstrated in this work, may enable detection of bloodborne pathogens from whole-blood specimens collected at the POC.
- 25 July 2022
- Published by Springer Nature in Nature Nanotechnology
- Vol. 17 (9) , 984-992
Multiplexed reverse-transcriptase quantitative polymerase chain reaction using plasmonic nanoparticles for point-of-care COVID-19 diagnosis
Quantitative polymerase chain reaction (qPCR) offers the capabilities of real-time monitoring of amplified products, fast detection, and quantitation of infectious units, but poses technical hurdles for point-of-care miniaturization compared with end-point polymerase chain reaction. Here we demonstrate plasmonic thermocycling, in which rapid heating of the solution is achieved via infrared excitation of nanoparticles, successfully performing reverse-transcriptase qPCR (RT-qPCR) in a reaction vessel containing polymerase chain reaction chemistry, fluorescent probes and plasmonic nanoparticles. The method could rapidly detect SARS-CoV-2 RNA from human saliva and nasal specimens with 100% sensitivity and 100% specificity, as well as two distinct SARS-CoV-2 variants. The use of small optical components for both thermocycling and multiplexed fluorescence monitoring renders the instrument amenable to point-of-care use. Overall, this study demonstrates that plasmonic nanoparticles with compact optics can be used to achieve real-time and multiplexed RT-qPCR on clinical specimens, towards the goal of rapid and accurate molecular clinical diagnostics in decentralized settings.
- 25 July 2022
- Published by Springer Nature in Nature Nanotechnology
- Vol. 17 (9) , 984-992
Multiplexed reverse-transcriptase quantitative polymerase chain reaction using plasmonic nanoparticles for point-of-care COVID-19 diagnosis
Quantitative polymerase chain reaction (qPCR) offers the capabilities of real-time monitoring of amplified products, fast detection, and quantitation of infectious units, but poses technical hurdles for point-of-care miniaturization compared with end-point polymerase chain reaction. Here we demonstrate plasmonic thermocycling, in which rapid heating of the solution is achieved via infrared excitation of nanoparticles, successfully performing reverse-transcriptase qPCR (RT-qPCR) in a reaction vessel containing polymerase chain reaction chemistry, fluorescent probes and plasmonic nanoparticles. The method could rapidly detect SARS-CoV-2 RNA from human saliva and nasal specimens with 100% sensitivity and 100% specificity, as well as two distinct SARS-CoV-2 variants. The use of small optical components for both thermocycling and multiplexed fluorescence monitoring renders the instrument amenable to point-of-care use. Overall, this study demonstrates that plasmonic nanoparticles with compact optics can be used to achieve real-time and multiplexed RT-qPCR on clinical specimens, towards the goal of rapid and accurate molecular clinical diagnostics in decentralized settings.